Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucose/Xylitol/L-carnitine peritoneal dialysis solution versus standard CAPD solutions
2009-016801-40Phase 2Terminated
- Sponsor
- Iperboreal Pharma
- Start
- Nov 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of levocarnitine, xylitol, glucose and icodextrin in end-stage kidney disease (ESKD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoints: Incidence and severity of adverse events, Patient perception of well-being questionnaire and 1 more. Started Nov 2010; status: terminated.
02
Drugs
levocarnitinexylitolglucoseicodextrin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2009-016801-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016801-40.